Cargando…

Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo

BACKGROUND: Vitiligo is an acquired autoimmune skin disorder. The often-visible lesions of vitiligo have a major impact on patients’ quality of life and the results of the treatment regimens on offer are unsatisfactory, so there is a need for new therapeutic regimens. Recent advances in vitiligo pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Samaka, Rehab M, Basha, Mohammed A, Menesy, Dina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612046/
https://www.ncbi.nlm.nih.gov/pubmed/31303777
http://dx.doi.org/10.2147/CCID.S210106
_version_ 1783432811551653888
author Samaka, Rehab M
Basha, Mohammed A
Menesy, Dina
author_facet Samaka, Rehab M
Basha, Mohammed A
Menesy, Dina
author_sort Samaka, Rehab M
collection PubMed
description BACKGROUND: Vitiligo is an acquired autoimmune skin disorder. The often-visible lesions of vitiligo have a major impact on patients’ quality of life and the results of the treatment regimens on offer are unsatisfactory, so there is a need for new therapeutic regimens. Recent advances in vitiligo pathogenesis have led to recognition of the importance of the JAK–STAT pathway as an attractive therapeutic option. PURPOSE: To evaluate role of JAK1 and STAT3 in vitiligo. METHODS: This prospective case–control study was carried out on 35 patients presenting with vitiligo and 20 apparently healthy age- and sex-matched volunteers. Skin biopsies from controls and cases were taken for histopathological and immunohistochemical JAK1 and STAT3 evaluation. RESULTS: Epidermal and dermal overexpression of STAT3 was noted in lesional skin compared to the other groups (P=0.02 and P<0.001, respectively). There was a positive correlation between dermal expression of JAK1 and dermal expression of STAT3 (r=0.52, P=0.004). CONCLUSION: In conjunction, JAK1 and STAT3 might be involved in the pathogenesis of vitiligo. This could open the gate for the use of JAK1 and STAT3 inhibitors as new targeted therapy for vitiligo.
format Online
Article
Text
id pubmed-6612046
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66120462019-07-14 Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo Samaka, Rehab M Basha, Mohammed A Menesy, Dina Clin Cosmet Investig Dermatol Original Research BACKGROUND: Vitiligo is an acquired autoimmune skin disorder. The often-visible lesions of vitiligo have a major impact on patients’ quality of life and the results of the treatment regimens on offer are unsatisfactory, so there is a need for new therapeutic regimens. Recent advances in vitiligo pathogenesis have led to recognition of the importance of the JAK–STAT pathway as an attractive therapeutic option. PURPOSE: To evaluate role of JAK1 and STAT3 in vitiligo. METHODS: This prospective case–control study was carried out on 35 patients presenting with vitiligo and 20 apparently healthy age- and sex-matched volunteers. Skin biopsies from controls and cases were taken for histopathological and immunohistochemical JAK1 and STAT3 evaluation. RESULTS: Epidermal and dermal overexpression of STAT3 was noted in lesional skin compared to the other groups (P=0.02 and P<0.001, respectively). There was a positive correlation between dermal expression of JAK1 and dermal expression of STAT3 (r=0.52, P=0.004). CONCLUSION: In conjunction, JAK1 and STAT3 might be involved in the pathogenesis of vitiligo. This could open the gate for the use of JAK1 and STAT3 inhibitors as new targeted therapy for vitiligo. Dove 2019-06-28 /pmc/articles/PMC6612046/ /pubmed/31303777 http://dx.doi.org/10.2147/CCID.S210106 Text en © 2019 Samaka et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Samaka, Rehab M
Basha, Mohammed A
Menesy, Dina
Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
title Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
title_full Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
title_fullStr Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
title_full_unstemmed Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
title_short Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
title_sort role of janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612046/
https://www.ncbi.nlm.nih.gov/pubmed/31303777
http://dx.doi.org/10.2147/CCID.S210106
work_keys_str_mv AT samakarehabm roleofjanuskinase1andsignaltransducerandactivatoroftranscription3invitiligo
AT bashamohammeda roleofjanuskinase1andsignaltransducerandactivatoroftranscription3invitiligo
AT menesydina roleofjanuskinase1andsignaltransducerandactivatoroftranscription3invitiligo